VICTORIA, BRITISH COLUMBIA--(Marketwire - Oct. 10, 2012) - MedGenesis Therapeutix Inc, a privately held biotechnology company focused on the development of definitive treatments for neurologic diseases, today announced that the Deutsche Parkinson Vereinigung e.V. has awarded a substantial grant to MedGenesis to support the Phase II development of glial cell line derived neurotrophic factor (GDNF).
"We are deeply appreciative to the Deutsche Parkinson Vereinigung for joining the alliance in support of our GDNF program in Parkinson's disease," said Dr. Erich Mohr, Chairman and CEO of MedGenesis. "GDNF has the potential to become the first disease-modifying treatment in Parkinson's disease and could significantly change the quality of life of the affected patients."
"On behalf of our association and all those patients suffering from Parkinson's disease, we are pleased to have the opportunity to support this program that may have a distinct impact on the disease and gives reason for hope to many patients," said Friedrich-Wilhelm Mehrhoff, Managing Director of the Deutsche Parkinson Vereinigung e.V.
About MedGenesis Therapeutix Inc.
MedGenesis is a privately-held biopharmaceutical company committed to developing and commercializing innovative therapeutics to provide life-enhancing treatments to patients with serious neurologic diseases. MedGenesis is a worldwide leader in convection-enhanced delivery (CED), a minimally invasive technique that provides for targeted, local treatment of serious conditions such as Parkinson's disease, epilepsy, brain cancer and other severely debilitating diseases of the central nervous system.
Learn more about MedGenesis at: www.medgenesis.com
About Deutsche Parkinson Vereinigung e.V.
The Deutsche Parkinson Vereinigung is a self-help organization that was founded in 1981 by people affected by Parkinson's disease. Today, the association has approximately 23,000 members and more than 450 regional groups and contact points. The aim of the Deutsche Parkinson Vereinigung is to improve the lives of Parkinson's patients and their partners. To that end, the association is committed to actively support research into new therapies and treatment approaches for Parkinson's disease. Another key concern is to provide patients with relevant information and strengthen their self-confidence to make them informed partners in the therapeutic alliance with their doctors and caregivers.
Learn more about Deutsche Parkinson Vereinigung e.V at: http://www.parkinson-vereinigung.de/
This news release contains certain forward looking statements that reflect the current views and/or expectations of the company with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly.